In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vital Signs, Dentsply complete acquisitions:

This article was originally published in Clinica

Executive Summary

This week saw both Vital Signs and Dentsply close acquisitions to boost geographic coverage and expand product range, respectively. Through its subsidiary Sleep Services of America, Vital Signs, the Totowa, New Jersey-based medical device manufacturer has completed the acquisition of Southern Sleep Technologies, a sleep diagnostics service provider, and Southern Home Respiratory Care, a CPAP (continuous positive airway pressure) equipment supplier for sleep apnoea patients (see Clinica No 1239, p 13). Dental products manufacturer Dentsply (York, Pennsylvania) has closed a deal to acquire all assets of Sultan Healthcare (see Clinica No 1263, p 14). Sultan, located in Englewood, New Jersey, will expand Dentsply's product portfolio with the addition of its line of dental consumables.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel